|40.18||+0.2100||+0.53%||Vol 1.01M||1Y Perf -38.17%|
|Apr 13th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||85.76||Analyst Rating||Strong Buy 1.40|
|Potential %||113.44||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||★★★ 51.17|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Market Cap||2.50B||Earnings Rating||Sell|
|Price Range Ratio 52W %||7.82||Earnings Date||5th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|12/2022 FY||-1.36||-1 800.00||Negative|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||-1.01|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||838.33K|
|Avg. Monthly Volume||805.41K|
|Avg. Quarterly Volume||981.82K|
Global Blood Therapeutics Inc. (NASDAQ: GBT) stock closed at 40.18 per share at the end of the most recent trading day (a 0.53% change compared to the prior day closing price) with a volume of 1.01M shares and market capitalization of 2.50B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 389 people. Global Blood Therapeutics Inc. CEO is Ted W. Love.
The one-year performance of Global Blood Therapeutics Inc. stock is -38.17%, while year-to-date (YTD) performance is -7.23%. GBT stock has a five-year performance of 95.9%. Its 52-week range is between 36.49 and 83.69, which gives GBT stock a 52-week price range ratio of 7.82%
Global Blood Therapeutics Inc. currently has a PE ratio of -10.20, a price-to-book (PB) ratio of 6.16, a price-to-sale (PS) ratio of 22.65, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -31.12%, a ROC of -43.35% and a ROE of -47.32%. The company’s profit margin is -%, its EBITDA margin is -339.20%, and its revenue ttm is $109.69 Million , which makes it $1.76 revenue per share.
Of the last four earnings reports from Global Blood Therapeutics Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-1.01 for the next earnings report. Global Blood Therapeutics Inc.’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Global Blood Therapeutics Inc. is Strong Buy (1.4), with a target price of $85.76, which is +113.44% compared to the current price. The earnings rating for Global Blood Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Global Blood Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Global Blood Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.83, ATR14 : 2.80, CCI20 : -97.07, Chaikin Money Flow : -0.04, MACD : -2.18, Money Flow Index : 34.11, ROC : -0.62, RSI : 39.29, STOCH (14,3) : 35.92, STOCH RSI : 0.91, UO : 42.94, Williams %R : -64.08), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Global Blood Therapeutics Inc. in the last 12-months were: Brian Edwin Cathers (Option Excercise at a value of $0), Brian Edwin Cathers (Sold 2 200 shares of value $140 294 ), David L. Johnson (Option Excercise at a value of $0), Dawn Svoronos (Option Excercise at a value of $0), Dawn Svoronos (Sold 5 088 shares of value $325 327 ), Deval L. Patrick (Option Excercise at a value of $0), Eric Fink (Option Excercise at a value of $0), Eric Fink (Sold 6 986 shares of value $442 771 ), Glenn Pierce (Option Excercise at a value of $225 450), Jeffrey S. Farrow (Option Excercise at a value of $0), Jeffrey S. Farrow (Sold 30 416 shares of value $2 159 536 ), Jung E. Choi (Option Excercise at a value of $0), Lesley Ann Calhoun (Option Excercise at a value of $593 585), Lesley Ann Calhoun (Sold 29 403 shares of value $2 195 189 ), Mark L. Perry (Option Excercise at a value of $1 053 500), Mark L. Perry (Sold 107 200 shares of value $8 372 120 ), Philip A. Pizzo (Option Excercise at a value of $0), Scott W. Morrison (Option Excercise at a value of $0), Ted W. Love (Option Excercise at a value of $0), Ted W. Love (Sold 85 634 shares of value $6 855 948 ), Tricia Borga Suvari (Option Excercise at a value of $0), Tricia Borga Suvari (Sold 4 080 shares of value $306 000 ), Wendy L. Yarno (Option Excercise at a value of $0), Willie Brown (Option Excercise at a value of $0)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.